Cargando…
Response to First-Line Antiretroviral Therapy Among PLHIV from a High-Risk, Low-Prevalence Setting
The study reports the response of first-line antiretroviral therapy (ART) by assessing CD4 and CD8 T-lymphocyte and viral load (VL) among Bangladeshi people living with HIV (PLHIV). This observational approach was conducted on 100 PLHIVs, grouped into therapy naive (n = 33), therapy initiators with...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900579/ https://www.ncbi.nlm.nih.gov/pubmed/31392926 http://dx.doi.org/10.1177/2325958219867329 |
_version_ | 1783477376588447744 |
---|---|
author | Rashed Ul Islam, Shahria Mohammad Jahan, Munira Nessa, Afzalun Tabassum, Shahina |
author_facet | Rashed Ul Islam, Shahria Mohammad Jahan, Munira Nessa, Afzalun Tabassum, Shahina |
author_sort | Rashed Ul Islam, Shahria Mohammad |
collection | PubMed |
description | The study reports the response of first-line antiretroviral therapy (ART) by assessing CD4 and CD8 T-lymphocyte and viral load (VL) among Bangladeshi people living with HIV (PLHIV). This observational approach was conducted on 100 PLHIVs, grouped into therapy naive (n = 33), therapy initiators with CD4 T-cell count of <350 cells/µL (n = 33), and therapy receivers for >1 year prior to the study period (n = 34). Therapy initiators who continued the study (n = 20) were followed up after 12 and 24 weeks of therapy initiation. The CD4 and CD8 T-lymphocyte count estimation and (VL) were quantified. The mean CD4 T-lymphocyte count was significantly reduced among the therapy initiators in comparison to therapy naive and therapy receivers. Similar findings were observed for CD8 T-lymphocyte count among the study groups. The mean HIV-1 RNA VL among therapy initiators showed a significant decrease after 12 and 24 weeks, and 85% patients in this group obtained undetectable VL status indicating the good therapeutic outcome. |
format | Online Article Text |
id | pubmed-6900579 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-69005792019-12-12 Response to First-Line Antiretroviral Therapy Among PLHIV from a High-Risk, Low-Prevalence Setting Rashed Ul Islam, Shahria Mohammad Jahan, Munira Nessa, Afzalun Tabassum, Shahina J Int Assoc Provid AIDS Care Original Article The study reports the response of first-line antiretroviral therapy (ART) by assessing CD4 and CD8 T-lymphocyte and viral load (VL) among Bangladeshi people living with HIV (PLHIV). This observational approach was conducted on 100 PLHIVs, grouped into therapy naive (n = 33), therapy initiators with CD4 T-cell count of <350 cells/µL (n = 33), and therapy receivers for >1 year prior to the study period (n = 34). Therapy initiators who continued the study (n = 20) were followed up after 12 and 24 weeks of therapy initiation. The CD4 and CD8 T-lymphocyte count estimation and (VL) were quantified. The mean CD4 T-lymphocyte count was significantly reduced among the therapy initiators in comparison to therapy naive and therapy receivers. Similar findings were observed for CD8 T-lymphocyte count among the study groups. The mean HIV-1 RNA VL among therapy initiators showed a significant decrease after 12 and 24 weeks, and 85% patients in this group obtained undetectable VL status indicating the good therapeutic outcome. SAGE Publications 2019-08-08 /pmc/articles/PMC6900579/ /pubmed/31392926 http://dx.doi.org/10.1177/2325958219867329 Text en © The Author(s) 2019 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Article Rashed Ul Islam, Shahria Mohammad Jahan, Munira Nessa, Afzalun Tabassum, Shahina Response to First-Line Antiretroviral Therapy Among PLHIV from a High-Risk, Low-Prevalence Setting |
title | Response to First-Line Antiretroviral Therapy Among PLHIV from a High-Risk,
Low-Prevalence Setting |
title_full | Response to First-Line Antiretroviral Therapy Among PLHIV from a High-Risk,
Low-Prevalence Setting |
title_fullStr | Response to First-Line Antiretroviral Therapy Among PLHIV from a High-Risk,
Low-Prevalence Setting |
title_full_unstemmed | Response to First-Line Antiretroviral Therapy Among PLHIV from a High-Risk,
Low-Prevalence Setting |
title_short | Response to First-Line Antiretroviral Therapy Among PLHIV from a High-Risk,
Low-Prevalence Setting |
title_sort | response to first-line antiretroviral therapy among plhiv from a high-risk,
low-prevalence setting |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900579/ https://www.ncbi.nlm.nih.gov/pubmed/31392926 http://dx.doi.org/10.1177/2325958219867329 |
work_keys_str_mv | AT rashedulislamshahriamohammad responsetofirstlineantiretroviraltherapyamongplhivfromahighrisklowprevalencesetting AT jahanmunira responsetofirstlineantiretroviraltherapyamongplhivfromahighrisklowprevalencesetting AT nessaafzalun responsetofirstlineantiretroviraltherapyamongplhivfromahighrisklowprevalencesetting AT tabassumshahina responsetofirstlineantiretroviraltherapyamongplhivfromahighrisklowprevalencesetting |